Adverts
![]() |
Image: Newspaper 316 |
Product developed by 60 researchers and approved by Anvisa began to be manufactured on a large scale on Tuesday (24).
Researchers from the University of São Paulo (USP) announced last Tuesday (24) the development of a mouthwash formula capable of inactivating the proliferation of the Sars-CoV-2 virus, which causes Covid-19, in 96%. The formula is based on PHTALOX® technology, a compound initially created to treat bad breath and improve gum health.
The research was conducted by the DentalClean Research and Innovation Center in partnership with four public institutions: the USP School of Dentistry in Bauru (SP), the USP Institute of Biological Sciences, the State University of Londrina (PR) and the Federal Institute of Paraná. The study is coordinated by Fabiano Vieira Vilhena, a public health dentist and researcher at USP, and involved 60 specialists.
From March to November, researchers completed six stages of the study involving 107 patients in laboratory tests, case series and triple-blind randomized clinical studies. In the first month, the virucidal action of the product was confirmed, which, from a formula manufactured for gum disease, was redirected to verify its effectiveness in preventing the transmission of Sars-CoV-2.
“Inactivating the transmission of the Covid-19 virus in the upper airways of the human body is one of the most effective ways to prevent the disease from progressing to the lower respiratory tract,” the scientists write. “The antiseptic is capable of blocking the virus in the oral cavity (mouth region), preventing it from gaining strength and advancing to the rest of the body.”
With the success of the tests, the product, called Detox Pro, was approved by Anvisa in October and, this Tuesday, the start of large-scale production was announced. “Today we started production of the first batch of this product, the 600 ml antiseptic,” said Giuliano Castro, national business manager at Dentalclean. “For the first quarter of 2021, the production estimate is more than 12 million units in the antiseptic, spray and dental gel categories.”
As demand increases, production can be increased. R$10 million was invested in product development and research.